Trial · Ohtsu et al., Digestion (2017)
Randomized Controlled Trial of LG21 Yogurt for H. pylori-Negative Functional Dyspepsia(opens in a new tab)
- Findings and study population
- In 116 H. pylori-negative adults with dyspepsia (per-protocol 106, mean age 42.8), LG21 (85g/day for 12 weeks) showed no significant difference on the primary global gastric assessment (p=0.073). Secondary major symptom elimination favored LG21 (35.3% vs 17.3%, p=0.048).
- Limitations and differences from this claim
- Small per-protocol cohort, non-significant primary endpoint, and corporate co-authorship. The 85g trial dose differs from the current 112g product. It evaluated uninfected individuals and does not establish H. pylori eradication.
Checked: